tolmar | fensolvi® (leuprolide acetate) for injectable suspension

An Educational Program Designed For Pediatric Healthcare Professionals

Clinical Considerations for Children With Central Precocious Puberty

With Fensolvi® Clinical Data Review

Program Objectives:

1. Understand and discuss central precocious puberty (CPP)
   - Diagnostic criteria
   - Treatment goals
   - When to initiate treatment
2. Discuss treatment options and clinical outcomes for children with CPP
3. Examine the use of Fensolvi in treating children with CPP

Program Length:

45-60 minutes

Where:

Your clinic or a location of your choosing (during work or after hours)

Presented by:

A Pediatric Endocrinology provider with extensive knowledge and clinical experience with Fensolvi.

See reverse for more details →

Schedule an in-person or virtual presentation

CONTACT
Pete McAdams
Director Strategic Partnerships, Tolmar
pete.mcadams@tolmar.com
615-481-1219

IMPORTANT SAFETY INFORMATION FOR FENSOLVI

FENSOLVI (leuprolide acetate) for injectable suspension is a gonadotropin releasing hormone (GnRH) agonist used to treat patients 2 years of age and older with central precocious puberty (CPP). CPP may be diagnosed when signs of sexual maturity begin to develop in girls under the age of 8 or in boys under the age of 9.

FENSOLVI is contraindicated in individuals with hypersensitivity to any drug that is in the same class as FENSOLVI, in individuals who are allergic to any of the ingredients in FENSOLVI, or in individuals who are pregnant. FENSOLVI may cause fetal harm when administered to a pregnant patient.

See additional Important Safety Information on reverse side.

tolmar | fensolvi® (leuprolide acetate) for injectable suspension

An Educational Program Designed For Pediatric Healthcare Professionals


This program is delivered by a Pediatric Endocrinology provider with extensive knowledge and clinical experience with Fensolvi®

Program Presenters:

- **Karen O. Klein,** MD
  Rady Children's Hospital
  San Diego, CA
- **Jadranka Popovic,** MD
  Medical University of South Carolina
  Charleston, SC
- **Kristin Sabanosh,** MSN, APN, CPNP, CDCES
  Atlantic Health Services Morristown Medical Center
  Morristown, NJ
- **Lawrence Silverman,** MD
  Atlantic Health System Goryeb Children's Hospital
  Morristown, NJ
- **Joshua Yang,** MD
  Orlando Health Arnold Palmer Hospital for Children
  Orlando, FL

Schedule an in-person or virtual presentation

CONTACT
Pete McAdams
Director Strategic Partnerships, Tolmar
pete.mcadams@tolmar.com
615-481-1219



IMPORTANT SAFETY INFORMATION FOR FENSOLVI (continued)

During the first few weeks of treatment, increases in gonadotropins and sex steroids above baseline may result in an increase in signs and symptoms of puberty including vaginal bleeding in girls.

Psychiatric events have been reported in patients taking GnRH agonists. Events include emotional lability, such as crying, irritability, impatience, anger, and aggression. Patients should be monitored for development or worsening of psychiatric symptoms.

Convulsions have been observed in patients treated with GnRH agonists with or without a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and in patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs.

Pseudotumor Cerebri (Idiopathic Intracranial Hypertension) has been reported in pediatric patients treated with GnRH agonists. Patients should be monitored for headache, papilledema and blurred vision.

The most common adverse events seen with FENSOLVI were: injection site pain, nasopharyngitis, pyrexia, headache, cough, abdominal pain, injection site erythema, nausea, constipation, vomiting, upper respiratory tract infection, bronchospasm, productive cough and hot flush.

Please see full Prescribing Information for more information at Fensolvi.com/hcp

© 2025 Tolmar, Inc. All rights reserved. Tolmar, Fensolvi and their associated logos are trademarks of the Tolmar Group. Third-party trademarks and product names belong to their respective owners. TPI.2025.eng.4902.v1 06/25

tolmar